Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer
Eleonora Pagan(University of Milano-Bicocca), Karin Ribi, Alberto Farolfi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Daniel Rauch(Washington University in St. Louis), Rossella Graffeo(Ente Ospedaliero Cantonale), Elisabetta Cretella(Ospedale di Bolzano), Rossana Berardi(Marche Polytechnic University), Andrea Freschi(Centro di Riferimento Oncologico), Eugênio Bucci(MultiMedica), Edda Simoncini(International Breast Cancer Study Group), Monica Giordano(Ospedale Sant'Anna), Ann H. Partridge(Dana-Farber Cancer Institute), Mariangela Ciccarese(Ospedale Vito Fazzi), Nadia Bianco(Istituti di Ricovero e Cura a Carattere Scientifico), Vincenzo Bagnardi(Cancer Research And Biostatistics), Shari Gelber(Frontier Science & Technology Research Foundation), Elena Seles(Ospedale degli Infermi), Adolfo Favaretto(Istituto Oncologico Veneto), Manuela Rabaglio(University Hospital of Bern), Friedemann Honecker(Ostschweizer Kinderspital), Olivia Pagani(Swiss Group For Clinical Cancer Research), Monica Ruggeri(International Breast Cancer Study Group), Markus Borner(University of Bern), Alessandra Franzetti-Pellanda(Clinica Luganese Moncucco), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Lorenzo Gianni
Cited by 6
Related Papers
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k